Genfit S.A. (EPA:GNFT)
5.10
-0.10 (-1.92%)
At close: Dec 12, 2025
Genfit Revenue
Genfit had revenue of 35.54M EUR in the half year ending June 30, 2025, with 135.16% growth. This brings the company's revenue in the last twelve months to 45.13M, down -43.93% year-over-year. In the year 2024, Genfit had annual revenue of 70.69M with 105.01% growth.
Revenue (ttm)
45.13M
Revenue Growth
-43.93%
P/S Ratio
5.63
Revenue / Employee
240.03K
Employees
180
Market Cap
253.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 70.69M | 36.21M | 105.01% |
| Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
| Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
| Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
| Dec 31, 2020 | 8.68M | -30.29M | -77.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
Genfit News
- 4 days ago - GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy - GlobeNewsWire
- 16 days ago - Genfit Appoints Pejvack Motlagh As Chief Medical Officer - Nasdaq
- 17 days ago - GENFIT Announces Appointment of new Chief Medical Officer - GlobeNewsWire
- 24 days ago - GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update - GlobeNewsWire
- 24 days ago - GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market - GlobeNewsWire
- 4 weeks ago - GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF - GlobeNewsWire
- 4 weeks ago - GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025 - GlobeNewsWire
- 6 weeks ago - Genfit (GNFT) Plans to Voluntarily Delist from Nasdaq - GuruFocus